Parmax Pharma Completes Preferential Allotment

Equity shares acquired: 22,80,444 | Warrants allotted: 17,16,574

Reader Takeaway: Promoter group increases stake, while future warrant conversion will expand the company's total diluted equity base.

What just happened

Parmax Pharma Ltd has executed a preferential allotment of equity shares and warrants, effective August 29, 2026. The move follows in-principle approval from the BSE. The promoter group has significantly increased its position, moving from a pre-acquisition holding of 21,70,164 shares to a post-acquisition total (shares plus warrants) of 61,67,179. The total diluted share capital of the company is now 90,24,031 shares.

Why this matters

This allotment shifts the control dynamics within the company. The promoter group now holds approximately 68.34% on a fully diluted basis. For retail investors, the primary takeaway is the change in the capital structure and the potential for future dilution. Existing shareholders should note that the conversion of the newly issued warrants into equity will increase the total number of outstanding shares, impacting earnings per share and relative voting power.

Participants

The acquisition involved several members of the promoter and promoter group, including Dhiren Chandulal Shah, Sunil Chinubhai Shah, and various Persons Acting in Concert (PAC) such as Dhairya Dhiren Shah, Hiren Pravin Doshi, and Sheetal Hiren Doshi, among others.

What to track next

The key development to watch is the timeline for the warrant conversion. Since 17,16,574 warrants are now outstanding, their conversion into equity is a critical event that will determine the final dilution impact on the company’s equity base.